Macquarie says Mesoblast's MSB's acquisition of Osiris's cultured stem-cell assets is a worrying sign for the industry. Whilst this transaction appears to offer little downside for MSB, they are concerned that a insider and pioneer is seemingly giving up on the industry. The low transaction price suggests both a low internal value placed on stem-cell therapies, and little interest from external parties.